Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Astrana Health, Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-82.7% vs price
Base Case (Median)
-58.3% vs price
Bull Case (75th pct.)
-53.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $0.83 | -97.7% | High (40%) |
| PE Comparable | $15.93 | -55.6% | Medium (25%) |
| Graham Number | $17.11 | -52.3% | High (80%) |
| EV/EBITDA | $14.01 | -60.9% | Medium (20%) |
| EV/FCF | $25.22 | -29.7% | Medium (20%) |
| Earnings Power Value | $3.59 | -90.0% | High (70%) |
Based on 6 out of 7 methods, ASTH appears overvalued at the current price of $35.88. The base case fair value of $14.97 implies 58.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.